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Background: Females with Xp;Yq translocations manifest short stature and normal fertility, but rarely have follow-up.
The study purpose was to define the phenotype of a family with t(X;Y)(p22.3;q11.2), determine long-term reproductive
function, and compare to all reported female cases.
Methods: Comprehensive clinical and molecular analyses were performed on the female proband, who had regular
menses, normal endocrine function, and three pregnancies spanning seven years–a normal liveborn male and two with
unbalanced translocations (liveborn female and stillborn male).
Results: The translocation truncated KAL1 and deleted 44 genes on der(X). Our report constitutes the longest follow-up
of an X;Y translocation female. She had no evidence of Kallmann syndrome, gonadoblastoma, or cardiovascular disease.
Detailed analysis of 50 published female cases indicated a uniform lack of follow-up and significant morbidity—intellectual
disability (10%), facial dysmorphism (28%), eye abnormalities (14%), and skeletal defects (28%).
Conclusions: Our findings indicate normal ovarian function to date in a woman with an t(X;Y)(p22.3;q11.2). However,
additional published studies in the literature suggest careful follow-up is necessary and contradict the generalization that
females with Xp;Yq translocations are usually normal except for short stature.
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KAL1 geneBackground
Translocations involving the X and Y chromosome may
affect reproductive function. They occur because of
pairing of homologous sequences of the pseudoautoso-
mal regions of Xp and Yq in paternal meiosis [1]. These
translocations are relatively rare in humans, but when
they occur, they usually involve cytogenetic breakpoints
at Xp22 and Yq11 [2]. The phenotype of affected indi-
viduals varies depending upon the number and specific
genes deleted from the X chromosome. Affected males
may present as stillborns or liveborn males with multiple
congenital anomalies depending upon the number of X* Correspondence: lalayman@gru.edu
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unless otherwise stated.chromosomal genes that are deleted [2]. In contrast, fe-
males with X;Y translocations are usually reported to
be short with normal intelligence and normal repro-
ductive function, but some may have mild intellectual
disability [2].
More than 50 X;Y translocation patients with break-
points at Xp22 and Yq11 have been reported [2-20], but
there are still many uncertainties regarding the specific
molecular breakpoints involved, the phenotype of males
and females, their long-term reproductive potential, and
the risk of gonadal tumor formation. An extensive
review of the literature indicates that of the reported
female cases, follow-up was only rarely reported and that
the phenotype is perhaps more severe than often stated
[2-20]. However, there is no comprehensive analysis of
the existing female cases to determine the prevalence of
the reproductive and nonreproductive phenotypes. WeThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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proband and her family with an unbalanced X;Y trans-
location ascertained when her stillborn male was karyo-
typed. Taking into account this case and a critical
evaluation of the literature, the purpose of the present
study was to determine: 1) the precise molecular break-
points of Xp22.31 and Yq11.2; 2) the phenotype of
affected males and females; 3) ovarian function and fer-
tility over time in the affected adult female; 4) the risk
for cardiac anomalies; 5) the potential for a gonadal
tumor in affected females and 6) comparison of this pro-
band with all t(X;Y)(p22)(q11) females reported in the
literature to understand the severity of the phenotype
for genetic counseling purposes.
Case presentation
At presentation, the proband was a 25-year-old white
female G2P1011 with regular menses, who conceived
spontaneously without medical intervention (Patient I1Figure 1 The pedigree, karyotype, and genetic map are shown for th
with unbalanced X;Y chromosome translocations is shown. Quarter shaded
a stillborn male with the der(X) chromosome. (B) Karyotype of t(X;Y)(p22;Yq
the karyotype in the female and corresponding karyotype in the stillborn m
map documents the 44 genes deleted from this der(X) chromosome. Sequ
the KAL1 gene in Xp22.3.in Figure 1A). Her physical exam was normal except for
short stature (4′9″). Her first pregnancy resulted in the
birth of a normal, healthy girl (II1) with short stature
(<2.5%), but her second pregnancy ended at 20 weeks
with the birth of a stillborn male (II2) with hydroceph-
alus (Figure 1A) who did not have a full autopsy. Of
interest, upon second trimester analyte screening, her
serum unconjugated estriol was undetectable. Karyotype
of the stillborn male II2 revealed 46,Y,der(X)t(X;Y)
(p22.3;q11.2). Fluorescent in situ hybridization (FISH)
demonstrated ish der(X)t(X;Y)(wcpY+,wcpX+), with the
presence of the KAL1 (Kallmann syndrome-1) region
and deletion of the STS (steroid sulfatase) locus, narrow-
ing the breakpoint region on Xp22.
Results
The female proband I1 had a complete history and phys-
ical exam. Ovarian reserve was assessed using enzyme
immunoassays for cycle day #2 serum follicle stimulatinge patient with the X;Y translocation. (A) The pedigree of the family
circles indicate females with the der(X) who have short stature. II-2 is
11) is shown. The der(X) is indicated by an arrow. (C) The ideogram of
ale. Y chromosome sequences are shown in gray shading. (D) Genetic
encing of the junction fragment shows that the breakpoint lies within
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(AMH). Since she later presented with infertility, a hys-
terosalpingogram and preconceptional labs were per-
formed, as was a semen analysis on her male partner.
Both the proband I1 and her prepubertal daughter II1
had an identical unbalanced translocation 46,X,der(X)t
(X;Y)(p22.3;q11.23) with the derivative X being deleted
of Xp22.3 to the terminus and containing Yq11.2 to the
telomere cytogenetically (Figure 1B and C). Interphase
FISH studies on the proband’s peripheral lymphocytes
demonstrated the presence of the X centromere (DXZ1+)
and Yq12 (DYZ1+), but not the Y centromere (DYZ3-),
indicating the presence of only Yq11q12 on the deriva-
tive (X) chromosome (Figure 1D). SNP arrays revealed
that the breakpoint resided within intron 6 of the KAL1
gene (NM_000216.2), indicating that this gene was dis-
rupted and that 44 genes in distal Xp22.3 were deleted
(Figure 1E). The junction fragment of the der(X)
chromosome was amplified using three sets of primers
that could only amplify the X and Y sequences, and
these were of the predicted sizes. Nested PCR products
generated the expected sized bands (Additional file 1:
Figure S1A). These PCR products were then purified
and sequenced, and both X and Y-specific sequences
were identified. The breakpoint on Xp22.31 is between
coordinates of 8,548,685 and 8,548,812 (within 128 bp)
and that on Yq11.2 is between coordinates of
15,989,009 and 15,989,287 (within 288 bp) using hg19
of the Human Genome Browser.
However, because of extremely high homology of
repeated sequences within these regions of Xp22 and
Yq11, the precise breakpoint was not able to be ascer-
tained. Sequenced tagged sites of the Y chromosome in-
dicated the presence of Yq11 sequences in this affected
female (Additional file 1: Figure S1B). No centromeric
sequences or SRY were identified.
At age 25, proband I1 had a cycle day #2 FSH =
5.9mIU/m L (2.8-11.3, follicular phase) supporting nor-
mal ovarian reserve [21]. Because of her extreme short
stature and the terminal Xp deletion, she had a cardiac
echo to assess her cardiac function and aortic diameter,
which was normal. Genetic counseling was provided,
which included the 50% risk that males would inherit
the der(X) chromosome and likely be stillborn and the
50% risk that female offspring would inherit the trans-
location and have short stature. The couple elected to
attempt conception without intervention, and had a
healthy, normal male II3 (presumably 46,XY—but they
declined a karyotype).
The proband I1 maintained regular menses, but at age
32, she presented with three years of infertility. Her
menses remained regular at 28–29 day intervals; and her
physical exam including cardiac and reproductive sys-
tems, was normal. Her daughter (II1) remained belowthe 3% for height and was being evaluated for attention
deficit disorder. The parents stated that the daughter
was currently receiving one-on-one help in school due
to difficulties in reading. During this one year follow-up
period, the proband had a cycle day #2 FSH = 2.5mIU
(2.8-11.3, follicular phase) and AMH= 5.2 ng/mL (1.1-
6.9), two widely utilized tests of ovarian reserve [21].
Cystic fibrosis carrier testing, rubella immunity, thyroid
studies, and prolactin were normal. A hysterosalpingo-
gram revealed a bicornuate vs. septate uterus, a patent
right tube, and no fill of the left tube (Figure 2). An
ultrasound on cycle day 6 showed a normal uterus
measuring 5.3 × 4.2 × 2.7 cm with a 3.3 mm (normal)
endometrium and normal ovaries—right: 2.8 × 1.9 ×
2.4 cm with a 7 mm follicle and 5 other smaller follicles;
left: 2.2 × 1.4 × 2.5 cm with 3 small follicles. It was sug-
gested she have ovarian tumor markers—inhibin A,
inhibin B, hCG, AFP, and LDH, but these were declined.
She underwent clomiphene/intrauterine insemination
(IUI) for four cycles with a 50 mg dose when there was
a follicle on the right. Her estradiols were at appropriate
preovulatory levels and ranged from 558–1395 pg/mL
on cycle day 10–14 during monitoring (Additional file 1:
Table S1) with at least one mature follicle. A serum
progesterone performed 8 days after the LH surge was
ovulatory. Total motile sperm ranged from 9–11 million
for IUIs done on cycle days 12–17. She did not conceive
after four cycles, but she continues to have regular
menses.
Discussion
Translocations involving the X and Y chromosomes are
uncommon, although more than 50 Xp;Yq translocation
cases have been reported worldwide [2,22]. In X;Y trans-
locations, the breakpoints typically involve Xp22 and
Yq11, which tend to result from pairing of homologous
sequences located within these regions [2,22]. This was
true in our translocation case, in which the sequenced
portions of the der(X) chromosome contained both long
interspersed nuclear elements (LINE/L1 and Line/L2
homologous sequences), enabling the exchange of gen-
etic material during male meiosis. We have mapped the
breakpoint of our patient with a 46,X,der(X)(t(X;Y)
(p22.3;q11.21) translocation using FISH and SNP arrays,
and cloned the breakpoint by long-range PCR and DNA
sequencing.
The phenotype of females with Xp22;Yq11 transloca-
tions is usually stated to be normal except for short stat-
ure [2,22]. However, there has been no comprehensive
analysis of published female cases, as most reports only
contain one or several affected females; and follow up
has only been reported for several patients. Upon an
extensive literature review, at least 50 females with
Xp22;Yq11 translocations have been reported (Table 1;
Figure 2 Hysterosalpingogram showing a bicornuate vs. septate uterus with a patent right tube indicated by free spill of contrast
(indicated by an arrow).
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lated female cases indicates that there is considerably
more phenotypic morbidity in many affected phenotypic
females than is generally thought (Tables 1 and 2)
[2-20]. We realize that there may be a certain degree of
publication bias in that more severe phenotypes may be
present in the literature. Nevertheless, this is the infor-
mation now available to evaluate the phenotypic effects
of this translocation.
While it is true that more than 90% of affected females
have short stature, other significant phenotypic findings
are commonly present and include mild intellectual dis-
ability (10%), facial dysmorphism (28%), eye abnormal-
ities (14%), and skeletal defects (28%). One of 29 (3%)
females had a congenital heart defect [20]. In cases
where the female has been characterized, fertility has
only been reported in 10 translocation patients and nine
conceived; however only 4/10 (40%) had a normal child
(Tables 1 and 2). Serum FSH to assess ovarian reserve
has been performed (and is normal) in ~20% (6/29) of
affected females, but was only reported in four postpu-
bertal females—the time when it has clinical significance
[23]. In the childhood period, FSH does not accurately
reflect ovarian function, as gonadal failure cannot be dif-
ferentiated from normal ovarian function [23]. Only
three reproductive aged Xp22;Yq11 females have had
short-term follow up, and no patient has had a cycle day
2–3 FSH (cycle day is not specified) or a random serum
AMH level analyzed for ovarian reserve [21]. Therefore,
ovarian reserve has not ever been adequately assessed in
these previously reported women. Interestingly, in allpublished cases, we could not find any reports of a
Xp22;Yq11 translocation female with a gonadoblastoma.
Our proband I1 is a normal female except for short
stature, who has demonstrated normal reproductive
function as evidenced by regular menses. Her ovarian re-
serve is normal with a normal cycle day #2 FSH at age
25; and normal day #2 FSH and AMH at age 32. She
also had normal ovulatory response to superovulation
with clomiphene. Her first child was a daughter (II1)
with the same unbalanced translocation, who is also nor-
mal except for extreme short stature and attention def-
icit disorder. She has not yet had breast development at
age 9. Short stature in these two females is at least par-
tially explained by the heterozygous loss of the SHOX on
the distal Xp22.3, which is thought to be involved in the
short stature of Turner syndrome [24]. Patients with
monosomy X (with or without mosaicism) have a 50%
risk of congenital cardiac anomalies [25], so this was a
concern in our patient who had monosomy for a large
telomeric region of Xp. However, she does not have any
murmurs and had a normal echocardiogram. She has
been without any cardiac symptoms during her 7 year
period of follow-up. These findings, as well as our iden-
tification of only one of 29 (3%) translocation patients
having a cardiac anomaly (an atrioseptal defect) in the
literature [20], suggest that the genes in this deleted re-
gion do not play a major role in the heart defects of
Turner syndrome. However, it is also possible that our
patient could develop aortic valve abnormalities and/or
a dilated aortic root in the future, so careful follow up is
recommended.
Table 1 Reported Females with Xp22;Yq11 Translocations
No. Reference Index Case Age at
dx





















n/a exploratory laparotomy revealed nl










FSH = 5.8 mU/ml Not
measured
n/a Bicornuate/slightly asymmetric with left
horn less developed and filiform, fibrous
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n/a Not given Two affected male
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n/a Normal uterus by u/s and visual exam





















28 30 yr Unknown Normal breasts;
Apparent fertility;
G1P1001; abnl son
151 cm Not measured Not
measured
Unknown Mildly short upper extremities; No









n/a Linear skin defects with scalded
appearance of upper neck & face, severe
bilateral microphthalmia, left corneal
opacity, syndactyly of 2nd/3rd toes of










n/a Bilateral microphthalmia, left orbital cyst,
linear skin defects on face, neck,
shoulder, & chest; anteriorly displaced
anus; 1 cm sacral nevus, lack of sphincter
control of bowel & bladder at 2 10/12 yr,































n/a Hypoplastic uterus, short tubes,
numerous follicles within ovaries; short
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prenatal 2 yr 10mo n/a n/a Short, 81.5
cm and 81
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Unknown No evidence of
ovarian failure
Short Not reported Not
measured
n/a Upslanting palpebral fissures, increased








n/a n/a Short Not measured Not
measured








Unknown No evidence of
ovarian failure
Short Not measured Not
measured
Unknown Low posterior hairline, short, distal









Unknown n/a Short Not measured Not
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n/a Madelung deformity; Small hands with
moderate camptodactyly of 2-5th digits
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34 NA NA Ascertained through
a son with LWD
150 cm Not measured Not
measured
n/a Bowing of radius & bilateral subluxation
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Not measured Not
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n/a Brachycephaly, mesomelia, mild
developmental delay (IQ = 83), global
motor delay, major linguistic deficits,











Unknown G6; 1 abnl male, 1
abnl female, 4 SABs
within 10 weeks
159 cm Not measured Not
measured









































n/a Facial dysmorphism (hypertelorism,
epicanthus, short philtrim, and simple
external ear; ASD, psychomotor delay,









Unknown G1, P1; abnormal
male
150 cm Not measured Not
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Table 2 Clinical characteristics of phenotypic females with Xp22;Yq11 translocations
Phenotype Total (percent) Details
All Ages Reproductive age
Reproductive
Fertility 9/29 (31%) 9/10 (90%)
Delivery of normal child 4/29 (13.8%) 4/10 (40%) 4 of 10 adults had a normal child
Uterine anomaly 2/29 (6.9%) Hypoplastic (n = 1); bicornuate (n = 1)
FSH Levels 6/29 (20.7%) 4/10 (40%) All normal, but only 4 of reproductive age & none were done on
cycle day 2-3
AMH Levels 0 None were reported
Follow up 11/29 (37.9%) 3/10 (30%) No reports of repeat FSH or fertility evaluation
Gonadoblastoma 0
Nonreproductive
Short stature 27/29 (93.1%)
Intellectual disability 3/29 (10.3%) Microcephaly/borderline ID (n = 1);Major language delay/mild ID with
IQ =70 (n = 1); Mild developmental delay, IQ = 83, global motor delay,
major linguistic deficits (n = 1)
Facial dysmorphism 8/29 (27.6%) Linear skin defects of face (n = 3); upslanting palpebral fissures,
brachycephaly, others
Eye abnormalities 4/29 (13.8%) Microphthalmia (n = 3); strabismus (n =1)
Cardiac defects 1/29 (3.4%) ASD
Skeletal defects 8/29 (27.6%) Madelung, mesomelia, camptodactyly, syndactyly, others
Only included in this table are patients 1–11 and 33–50 since the details from Hsu (cases 9–29) are not provided. There are a total of 29 patients (all ages) and 11
that are reproductive age (defined as ≥17 years). ID = intellectual disability, ASD = atrial-septal defect. For full details including references, see Table 1.
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born male II2 with hydrocephalus, who inherited the
derivative X chromosome from his mother. Since
approximately 9.5 Mb of distal Xp containing 44 genes
is deleted in this male, this likely resulted in embryonic
lethality. Many of these genes are recognized to be
involved in human genetic diseases and include: SHOX
(dyschondrosteosis or Leri-Weill syndrome) [24],
NLGN4 (autism and intellectual disability) [26], ARSE
(chrondrodysplasia punctata, which has skeletal abnor-
malities and microcephaly) [27], VCX3A (implicated in
intellectual disability) [28], and STS (ichthyosis) [29].
Since KAL1 is directly interrupted, it is likely this male
would also have had Kallmann syndrome had he sur-
vived [30,31]. However, since this is an X-linked reces-
sive disorder not affecting women, it is not expected
that his mother would be affected with hypogonadotropic
hypogonadism or anosmia (and she was not).
This couple received genetic counseling, including the
possibility of preimplantation genetic diagnosis, which
they declined. Fortunately, our proband had a normal
term delivery of a reportedly normal male II3 in a subse-
quent pregnancy. The segregation of the der(X) within
the family is what would be predicted. Since the mother
is heterozygous for the der(X), she has a 50:50 chance of
transmitting this to female offspring so that half of fe-
males would be expected to be short with other possible
anomalies and the other half normal. In contrast, shehas a 50:50 chance of passing the der(X) to a male which
would result in deletion of 44 genes and probable lethality.
If a male received her normal X chromosome, he would
be expected to be normal. Although not karyotyped, her
normal son is presumably 46,XY.
The presence of Yq11q12 sequences on der(X) in the
female proband is unlikely to affect the phenotype.
Since SRY (sex determining region on the Y chromo-
some) is localized to the distal Yp arm, its absence did
not interfere with female sexual development. One to
two megabase sequences in the pericentromeric region
of Y, which may contain GBY (gonadoblastoma locus
on the Y chromosome), are thought to contribute to
the risk of gonadoblastomas and subsequent germ cell
neoplasms of the ovaries in females with a Y chromosome
[32]. Our patient has no evidence for this phenotype, and
this is understandable given that the breakpoint at Yq11.21,
which when revised after breakpoint cloning, is about
3.5 Mb away from this centromeric region. It is also pos-
sible that the GBY locus is in the pericentromeric region of
Yp, which is not present in our patient. TSPY, another pu-
tative gonadoblastoma locus, is also localized to Yp and
should not be present in this female proband. It is also re-
assuring that we were unable to document a female with
t(X;Y)(p22;q11) with a gonadoblastoma (Tables 1 and 2).
However, caution must be exercised since many of these
patients had no published follow up, and follow up with
tumor markers could be considered in her long term care.
Table 3 Primers used to amplify the junction fragments
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genesis genes documenting the presence of euchromatin
on the der(X), but they are unlikely to be of any clinical
significance in females. Our patient also had a uterine
anomaly. Uterine anomalies were present in two of 29
cases found in the literature—one hypoplastic [11] and
one bicornuate [4](Tables 1 and 2). However, it is un-
known whether or not the translocation contributed to
the (likely) bicornuate uterus in our patient.
Conclusion
In conclusion, mapping the breakpoint and cloning the
junction fragment of the der(X) chromosome in our pa-
tient with a Xp22;Yq11 translocation resulted in the iden-
tification of a 9.5 Mb deletion of distal Xp22, which
contains 44 genes. Our findings suggest that this der(X) in
affected females: 1) does not affect regular menstruation
or ovarian reserve; 2) does not preclude fertility; 3) results
in short stature; 4) does not result in gonadoblastomas in
females by age 32; 5) does not result in structural cardiac
disease in females like 45,X individuals; and 6) results in
the loss of 44 genes that collectively are probably lethal in
affected males. Additionally, significant morbidity in the
form of intellectual disability (10%), facial dysmorphism
(28%), eye abnormalities (14%), and skeletal defects (28%)
may occur in affected females, which should be considered
in the genetic counseling of these patients.
Methods
When the patient was seen at Georgia Regents Univer-
sity, karyotypes were performed on the proband I1 and
her healthy daughter II1 using standard G banding
methods from peripheral white blood cells (WBCs) [33].
She signed a consent to have her records reviewed and
to have blood drawn for molecular studies, which were
approved by the Human Assurance Committee of
Georgia Regents University. A lymphoblastoid cell line
was created by infecting WBCs with Epstein-Barr virus
and using cyclosporine A as described previously [34].
FISH was performed on metaphase chromosomes using
standard methods with five fluorescently labeled probes
including: X centromere (DXZ1), Y centromere (DYZ3),
Yq12 (DYZ1), STS, and KAL1 genes. A Genome-Wide
Human SNP Array 6.0, which features 1.8 million gen-
etic markers, including more than 906,600 single nucleo-
tide polymorphisms (SNPs) and more than 946,000
probes, was used to exclude copy number variants
(CNV) and narrow the breakpoint. The Affymetrix Gen-
eChip Command Console (AGCC) was used to scan the
chips and the Genotype Console 2.0 was used to analyze
the data to generate microarray results.
Long–range polymerase chain reaction (PCR) was per-
formed to amplify the junction fragment of the derivative X
chromosome. Primers were designed to amplify onlyfragments that contained both X and Y sequences (Table 3).
Primers were Y-2040for and X-4177rev (to yield a 9 kb frag-
ment), Y-6440for and X-2150rev (to yield a 4 kb fragment),
and Y-4140for and X-5891rev (to yield a 10 kb fragment).
PCR conditions included a 93°C denaturation step for 3 mi-
nutes, followed by 35 cycles of 93°C for 15 seconds, 62°C
for 30 seconds, and 68°C for 10 minutes. PCR products
were then electrophoresed on 1.2% agarose gels in the pres-
ence of a molecular weight marker, stained with ethidium
bromide, and photographed. Nested PCR using internal
primers was then used to amplify the junction fragment of
the breakpoint region. The resulting PCR products were
then ethanol precipitated and sequenced using the dideoxy
method with the Big Dye Terminator Kit and run on the
ABI 310 Automated DNA Sequencer [35]. Multiple bio-
informatic databases were utilized including Human Gen-
ome Browser (http://genome.ucsc.edu/), Repeat Masker
Web Server (http://www.repeatmasker.org/cgi-bin/WEBRe-
peatMasker), ClustalW2 (http://www.ebi.ac.uk/Tools/clus-
talw2/index.html) and WWW READSEQ Sequence
Conversion (http://www-bimas.cit.nih.gov/molbio/readseq).
To determine which Yq11 sequences were contained in
the der(X) chromosome, 19 sequence tagged sites (STS) on
various regions were amplified according to the instruc-
tions of the Y Chromosome Deletion Detection System
Version 2.0 (Promega; Madison, WI) and electrophoresed
on 1.2% agarose gels.
Additional file
Additional file 1: Figure S1. (A) Agarose gel electrophoresis showing
successful amplification of the junction fragment (see Methods). These
two PCR products were the expected size using X forward primer and Y
reverse primers (lanes 1 and 2). A molecular weight marker is shown in
lane 3. (B) Sequence tagged sites of the Y chromosome indicate the
presence of Yq11 sequences. F = female with der(X); M = control male;
C = negative control, which contains all reagents except for DNA; L = 123
base pair ladder, which was used as a molecular marker. Figure S2. FISH
analysis of metaphase chromosomes shows the derivative chromosome
der(X) as indicated by the presence of centromeric DXZ1 and the absence
of Y centromeric DYZ3. Also shown is the presence of KAL1 on both of her
X chromosomes and the absence of STS on one of the X chromosomes,
suggesting that the breakpoint lies between the two genes. Table S1. Four
clomiphene (50 mg/day cycle days 3–7)/intrauterine inseminations (IUI).
Ovulation was documented in one cycle with a serum progesterone
>20 ng/mL (>3 ng/mL is ovulatory). CD = cycle day.
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